Gut Microbiota and Extraintestinal Cancers: Mechanistic Insights and Microbiome‐Targeted Interventions Authors: Rishi Chowdhary, Manjeet Kumar Goyal, Kirti Arora, Tanisha Sehgal, Prachi Dawer, F N U Anirudh, Jeffrey Berinstein, Shrinivas Bishu, Laurie Matt‐Amaral Published: 2026 ABSTRACT ABSTRACTThe gut microbiota is a dynamic community of bacteria, viruses, fungi, and archaea that plays a pivotal role in regulating host immunity, metabolism, and systemic homeostasis. Dysbiosis, characterized by an imbalance in the microbial composition, is being increasingly recognized as a contributor not only to gastrointestinal cancers but also to extraintestinal malignancies. Mechanistic studies highlight the gut–microbiota–cancer axis, where microbial metabolites such as bile acids, short‐chain fatty acids (SCFAs), and tryptophan derivatives influence genetic, epigenetic, and immune pathways, influencing carcinogenesis. Germ‐free models demonstrate that commensal signals are essential for CD4+ and CD8+ T‐cell differentiation, IgA production, and anti‐tumor immunity. Dysbiosis‐induced immune dysregulation is believed to impair immune checkpoint inhibitor (ICI) efficacy, while specific taxa such as Bifidobacterium and Akkermansia have been shown to enhance therapeutic responses. Emerging evidence links gut microbiota to breast cancer via estrogen metabolism “estrobolome” to lung cancer through the gut–lung axis and modulation of ICI responses, to melanoma by shaping systemic T‐cell function and immunotherapy outcomes, and to prostate cancer through androgen receptor signaling and microbial metabolite interactions. These findings underscore the systemic oncogenic and tumor‐suppressive potential of microbial communities. Microbiome‐targeted interventions, including fecal microbiota transplantation (FMT), defined live biotherapeutics, probiotics, prebiotics, dietary modulation, and postbiotic delivery, are being actively investigated to optimize cancer treatment. While early trials have demonstrated feasibility, variability between individuals and methodological challenges remain significant hurdles. Hence, understanding how gut microbes influence extraintestinal cancers could revolutionize diagnostics, risk prediction, and treatment strategies. Introduction The gastrointestinal tract harbors a diverse community of microorganisms, collectively known as the gut microbiota, which includes bacteria, viruses, fungi, and archaea. These microbial inhabitants play a vital role in numerous physiological functions such as digestion and the production of vital metabolites like vitamins and short‐chain fatty acids (SCFAs). The gut microbiota is also instrumental in maintaining systemic homeostasis, regulating metabolic pathways, and protecting against pathogenic colonization. Gut dysbiosis has been implicated in a range of disorders, including metabolic diseases, autoimmune conditions such as inflammatory bowel disease, and various cancers [1]. The gut‐microbiota‐cancer axis describes how microbial communities influence tumorigenesis via metabolic reprogramming, immune modulation, and inflammatory signaling. Microbial metabolites such as bile acids and SCFAs can modulate host cellular pathways, thereby contributing to tumor initiation and progression. Additionally, dysbiosis may create a pro‐tumorigenic environment [2]. Understanding this axis offers opportunities for diagnostic and therapeutic innovation (Figure 1). Gut microbiota with tumor‐promoting and tumor‐suppressive effects. Enterotoxigenic Bacteroides fragilis, Fusobacterium nucleatum, Lactobacillus, and Proteobacteria promote oncogenesis through inflammatory signaling, estrogen reactivation, and hormone‐driven pathways. In contrast, Akkermansia muciniphila enhances anti‐tumor immunity and response to immune checkpoint blockade, Bifidobacterium species stimulate dendritic cells and CD8+ T‐cell activity, Ruminococcaceae support systemic and tumor‐infiltrating immune responses through short‐chain fatty acid production, and Faecalibacterium prausnitzii modulates inflammation via butyrate. These taxa collectively highlight the dual role of the gut microbiota in shaping cancer progression and therapeutic outcomes. The link between Helicobacter pylori infection and gastric cancer exemplifies the direct role of microbiota in carcinogenesis. This foundational discovery has spurred interest in the role of gut microbiota in non‐gastric cancers. Emerging evidence suggests that microbial dysbiosis may also contribute to the pathogenesis of extra‐gastrointestinal malignancies, highlighting the systemic influence of gut microbial populations [3]. Recent advancements have further delineated the gut microbiota's contribution to carcinogenesis. Dysbiosis may influence tumor development through the production of microbial metabolites, such as bile acids, SCFAs, and tryptophan derivatives that modulate genetic and epigenetic regulation, combat subsequently impacting immune cell metabolism and function. Depending on the microbial composition and the nature of these metabolic products, such interactions may either promote or inhibit tumorigenesis [4]. Although the link between gut microbiota and gastrointestinal malignancies is well documented, emerging evidence indicates that dysbiosis may also impact distant organs, possibly through systemic inflammation and immunological regulation [5]. Given its expanding role in cancer biology, the gut microbiota has garnered attention not only as a contributor to carcinogenesis but also as a potential biomarker for cancer risk stratification and a target for microbiome‐based therapies. The current review focuses on breast cancer, lung cancer, melanoma, and prostate cancer, as these malignancies currently provide the most robust mechanistic, translational, and early clinical evidence linking gut microbiome composition and function to tumor biology and therapeutic responsiveness. For other tumor types, existing data remain limited; therefore, they are not included to preserve depth and interpretive rigor. Key gut microbial taxa implicated in extraintestinal malignancies are summarized in Table 1. TABLE 1Gut microbial taxa linked to non‐gastrointestinal malignancies: mechanisms and tumor associations.Microbial taxonAssociated cancersReported function/mechanismAssociation (pro‐tumor vs. anti‐tumor) Bifidobacterium (genus) [6]Melanoma (solid tumor) Enhances anti‐tumor immunity and CD8+ T‐cell responses.Synergizes with PD‐1/PD‐L1 inhibitors (nearly eliminated tumors in mice). Anti‐tumor: promotes tumor rejection Akkermansia muciniphila [7, 8]Non–small cell lung cancer; renal and urothelial cancers (under immunotherapy); prostate cancer (under ADT) Enhances immunotherapy responses and immune modulation.Enriched in PD‐1 responders (NSCLC, RCC), restored PD‐1 sensitivity in mice.Supports anti‐tumor immunity and epithelial barrier integrity. Anti‐tumor: better treatment response and tumor control Enterococcus hirae [9]Lung and ovarian cancers (CTX chemotherapy) Translocates to lymphoid organs after cyclophosphamide, inducing Th1 immunity and increasing CD8+ T cells/CD8: Treg ratio. Anti‐tumor: improves chemo‐immunotherapy efficacy (immune stimulation) Barnesiella intestinihominis [9]Lung and ovarian cancers (CTX chemotherapy) Gut outgrowth during CTX therapyPromotes IFN‐γ + γδ T cell tumor infiltration and killing.Elicits memory Th1 responses linked to better patient outcomes. Anti‐tumor: enhances therapy‐induced anti‐tumor immunity Prevotella stercorea [10]Prostate cancer (castration‐resistant) Slowed CRPC tumor growth in mice via oral supplementation or fecal transfer.Mechanism likely involves altered bile acids or immune signaling opposing androgen‐producing bacteria. Anti‐tumor: linked to suppressed prostate tumor growth under androgen deprivation Eubacterium hallii [11]Multiple myeloma (hematologic cancer) Butyrate‐producing commensal with anti‐inflammatory and immunoregulatory effects.Higher abundance in myeloma patients achieving MRD negativity (better outcomes).Contributes to anti‐tumor microenvironment possibly via Treg modulation or improved gut barrier. Anti‐tumor: associated with favorable prognosis (deeper remission in MM) Ruminococcus gnavus [10]Prostate cancer (castration‐resistant) Ferments dietary components producing metabolites including androgens.Expands under androgen deprivation and converts androgen precursors into active androgens, fueling tumor progression. Pro‐tumor: promotes hormone‐driven tumor resistance and growth Klebsiella pneumoniae [11]Multiple myeloma (MM) (bone marrow cancer) Nitrogen‐recycling bacterium that metabolizes urea into glutamine, heavily utilized by MM cells.Colonization increased systemic glutamine and significantly accelerated myeloma progression in mice.Glutamine restriction blunted this effect. Pro‐tumor: feeds tumor metabolism, accelerating growth Prevotella heparinolytica [12]Multiple myeloma (hematologic cancer) Induces pro‐tumor immunity by stimulating gut Th17 cell differentiation. These cells migrate to bone marrow and secrete IL‐17, creating inflammatory conditions supporting myeloma progression. Pro‐tumor: drives IL‐17–mediated tumor growth Bacteroidales spp. (e.g., Bacteroides) [7]Melanoma, NSCLC (under immunotherapy) Higher abundance in non‐responders may impair T‐cell responses via immunosuppressive metabolites or Treg induction.Fecal samples from PD‐1 non‐responders (rich in Bacteroidales) conferred immunotherapy resistance in germ‐free mice (responders had low Bacteroidales and high SCFA‐producers). Pro‐tumor: hinders anti‐tumor immunity (correlated with checkpoint inhibitor resistance) Note: This table summarizes selected gut microbial taxa with established or emerging roles in modulating the progression or treatment response of non‐gastrointestinal (non‐GI) cancers. Microbial functions are categorized based on immunomodulation, metabolic reprogramming, or therapeutic synergy. The “Association” column classifies each taxon as either pro‐tumor or anti‐tumor based on experimental and clinical evidence.Abbreviations: ADT, androgen deprivation therapy; CRPC, castration‐resistant prostate cancer; CTX, chemotherapy; IFN‐γ, interferon‐gamma; IL‐17, interleukin‐17; MM, multiple myeloma; MRD, minimal residual disease; NSCLC, non–small cell lung cancer; PD‐1/PD‐L1, programmed death‐1/programmed death‐ligand‐1; RCC, renal cell carcinoma; SCFA, short‐chain fatty acid; Th1/Th17, T‐helper type 1/type 17 cells; Treg, regulatory T cell. Gut microbial taxa linked to non‐gastrointestinal malignancies: mechanisms and tumor associations. Enhances anti‐tumor immunity and CD8+ T‐cell responses. Enhances anti‐tumor immunity and CD8+ T‐cell responses. Synergizes with PD‐1/PD‐L1 inhibitors (nearly eliminated tumors in mice). Synergizes with PD‐1/PD‐L1 inhibitors (nearly eliminated tumors in mice). Enhances immunotherapy responses and immune modulation. Enhances immunotherapy responses and immune modulation. Enriched in PD‐1 responders (NSCLC, RCC), restored PD‐1 sensitivity in mice. Enriched in PD‐1 responders (NSCLC, RCC), restored PD‐1 sensitivity in mice. Supports anti‐tumor immunity and epithelial barrier integrity. Supports anti‐tumor immunity and epithelial barrier integrity. Translocates to lymphoid organs after cyclophosphamide, inducing Th1 immunity and increasing CD8+ T cells/CD8: Treg ratio. Translocates to lymphoid organs after cyclophosphamide, inducing Th1 immunity and increasing CD8+ T cells/CD8: Treg ratio. Gut outgrowth during CTX therapy Gut outgrowth during CTX therapy Promotes IFN‐γ + γδ T cell tumor infiltration and killing. Promotes IFN‐γ + γδ T cell tumor infiltration and killing. Elicits memory Th1 responses linked to better patient outcomes. Elicits memory Th1 responses linked to better patient outcomes. Slowed CRPC tumor growth in mice via oral supplementation or fecal transfer. Slowed CRPC tumor growth in mice via oral supplementation or fecal transfer. Mechanism likely involves altered bile acids or immune signaling opposing androgen‐producing bacteria. Mechanism likely involves altered bile acids or immune signaling opposing androgen‐producing bacteria. Butyrate‐producing commensal with anti‐inflammatory and immunoregulatory effects. Butyrate‐producing commensal with anti‐inflammatory and immunoregulatory effects. Higher abundance in myeloma patients achieving MRD negativity (better outcomes). Higher abundance in myeloma patients achieving MRD negativity (better outcomes). Contributes to anti‐tumor microenvironment possibly via Treg modulation or improved gut barrier. Contributes to anti‐tumor microenvironment possibly via Treg modulation or improved gut barrier. Ferments dietary components producing metabolites including androgens. Ferments dietary components producing metabolites including androgens. Expands under androgen deprivation and converts androgen precursors into active androgens, fueling tumor progression. Expands under androgen deprivation and converts androgen precursors into active androgens, fueling tumor progression. Nitrogen‐recycling bacterium that metabolizes urea into glutamine, heavily utilized by MM cells. Nitrogen‐recycling bacterium that metabolizes urea into glutamine, heavily utilized by MM cells. Colonization increased systemic glutamine and significantly accelerated myeloma progression in mice. Colonization increased systemic glutamine and significantly accelerated myeloma progression in mice. Glutamine restriction blunted this effect. Glutamine restriction blunted this effect. Induces pro‐tumor immunity by stimulating gut Th17 cell differentiation. These cells migrate to bone marrow and secrete IL‐17, creating inflammatory conditions supporting myeloma progression. Induces pro‐tumor immunity by stimulating gut Th17 cell differentiation. These cells migrate to bone marrow and secrete IL‐17, creating inflammatory conditions supporting myeloma progression. Higher abundance in non‐responders may impair T‐cell responses via immunosuppressive metabolites or Treg induction. Higher abundance in non‐responders may impair T‐cell responses via immunosuppressive metabolites or Treg induction. Fecal samples from PD‐1 non‐responders (rich in Bacteroidales) conferred immunotherapy resistance in germ‐free mice (responders had low Bacteroidales and high SCFA‐producers). Fecal samples from PD‐1 non‐responders (rich in Bacteroidales) conferred immunotherapy resistance in germ‐free mice (responders had low Bacteroidales and high SCFA‐producers). Note: This table summarizes selected gut microbial taxa with established or emerging roles in modulating the progression or treatment response of non‐gastrointestinal (non‐GI) cancers. Microbial functions are categorized based on immunomodulation, metabolic reprogramming, or therapeutic synergy. The “Association” column classifies each taxon as either pro‐tumor or anti‐tumor based on experimental and clinical evidence. Abbreviations: ADT, androgen deprivation therapy; CRPC, castration‐resistant prostate cancer; CTX, chemotherapy; IFN‐γ, interferon‐gamma; IL‐17, interleukin‐17; MM, multiple myeloma; MRD, minimal residual disease; NSCLC, non–small cell lung cancer; PD‐1/PD‐L1, programmed death‐1/programmed death‐ligand‐1; RCC, renal cell carcinoma; SCFA, short‐chain fatty acid; Th1/Th17, T‐helper type 1/type 17 cells; Treg, regulatory T cell. Mechanism of Gut Microbiota Influence The gut microbiota influences the immunopathogenesis of malignancies by affecting the tumor microenvironment. Microbial communities can either enhance anti‐tumor immunity or facilitate immunization through interactions with immune cells, cytokine production, and regulation of immune checkpoints. Through diverse mechanisms the gut microbiota profoundly affects both innate and adaptive immune system thereby influencing cancer initiation and progression [13]. It plays a pivotal role in the maturation and regulation of immune cells including T lymphocytes and macrophages [14]. Among these, intestinal CD4+ T cells, located in the lamina propria (LP)–are particularly sensitive to microbial cues. Upon specific stimulation, naïve CD4+ T cells undergo class switching and differentiate into T helper 1 (Th1), Th2, Th17, and regulatory T cells (Treg), which are an integral part of maintaining immune homeostasis (Figure 2) [15]. One effective method that highlights the significance of the microbiota in influencing both innate and adaptive immunity is the use of germ‐free (GF) models, in which animals are raised in a sterile environment and have never been exposed to any microbes [16]. In GF mice, the quantity of LP CD4+ cells is markedly reduced, which again emphasizes the pivotal role of microbiome in immune regulation [17]. Similarly, the intra‐epithelial compartment of the gut, which contains most intestinal CD8+ T lymphocytes, demonstrates reduced cytotoxic activity and cell counts in GF models, indicating that microbiota‐derived signals are essential for sustaining intestinal CD8+ T cell function and population [18, 19, 20]. Moreover, gut microbiota is crucial for conditioning CD8+ T cells, which influences other peripheral immune cells, including invariant natural killer T cells, plasmacytoid dendritic cells (DCs), and marginal zone B cells [21, 22, 23]. The majority of gut‐associated B cells, which are plasma cells that secrete immunoglobulin (Ig) A, are located in Peyer's patches. GF animals show a significant drop in the quantity and cellularity of Peyer's patches, which in turn led to a lower level of IgA and fewer plasma cells in their intestines [24]. As summarized in Table 2. Gut microbiota‐mediated modulation of cancer progression. The intestinal microbiota is fundamental for maintaining barrier integrity, protecting against pathogens, and shaping host immune responses. However, dysbiosis or the presence of invasive bacteria can shift this balance toward tumor promotion. Certain microbial species, such as Bacteroides fragilis and some strains of Lactobacillus and Proteobacteria, release metabolites including lipopolysaccharides (LPS) and peptidoglycans that activate pattern recognition receptors (PRRs). This activation drives macrophage polarization toward a pro‐inflammatory M1 phenotype and alters dendritic cell–mediated T cell priming, ultimately leading to chronic inflammation and impaired immune surveillance. Moreover, some microbial metabolites suppress T cell recognition of tumor‐associated antigens, diminishing CD8+ cytotoxic responses in the tumor microenvironment. Collectively, these mechanisms weaken host anti‐tumor immunity and create a permissive environment for tumor growth and progression. CTL, cytotoxic T lymphocyte; DC, dendritic cell; IL‐12, interleukin 12; MHC‐I, major histocompatibility complex class I; MHC‐II, major histocompatibility complex class II; NK, natural killer; PRR, pattern recognition receptor; TCR, T cell receptor. TABLE 2Gut microbiota–cancer interactions across human and animal studies.Cancer typeMicrobial taxa investigatedStudy design (human vs. animal)Main findingsLung cancer (NSCLC) [25]Commensal gut microbiota (mixed taxa; broad depletion)Animal (mouse model of lung adenocarcinoma) Germ‐free or antibiotic‐treated mice (Kras^G12D^/+; p53^−/−^ lung tumor model) developed fewer tumors.Gut microbes promoted tumor via IL‐1β/IL‐23 signaling and γδ T cell expansion.Removing gut microbes or blocking γδ T cells suppressed microbiota‐driven immune activation to lung cancer growth. Lung cancer (NSCLC) [26] Akkermansia muciniphila , Alistipes onderdonkii , Ruminococcus (gut taxa)Human (clinical observational) Lower gut diversity in patients; high A. muciniphila correlated with longer progression‐free survival.Other taxa (e.g., Alistipes onderdonkii , Ruminococcus) serve as prognostic biomarkers or therapeutic targets in NSCLC. Melanoma (checkpoint therapy) [6] Bifidobacterium spp.Animal (mouse melanoma model) Bifidobacterium enhanced dendritic cell and CD8+ T‐cell function, to a similar extent as anti–PD‐L1 immunotherapy; combination nearly abolished tumor growth.This study was among the first to show that a gut commensal can boost systemic anti‐cancer immunity. Melanoma (checkpoint therapy) [27] Ruminococcaceae family, diverse gut floraHuman (observational + FMT to mice) Responders had higher microbiome α‐diversity and higher abundance of Ruminococcaceae; responder‐FMT (Fecal microbiota transplant) improved tumor control in mice non‐responders.This indicates the gut microbiota composition causally influenced immunotherapy efficacy in melanoma. Multiple cancers (melanoma, lung, kidney) [28] Akkermansia muciniphila , Ruminococcus spp.Human (observational cohorts + mouse FMT) Antibiotic use linked to poorer outcomes in advanced lung, renal, and bladder cancer patients.Certain gut bacteria, notably Akkermansia muciniphila (and some Ruminococcus spp.) restored PD‐1 efficacy in mice.This demonstrates specific gut microbes (like Akkermansia) can enhance anti‐tumor immunity and improve immunotherapy success. Breast cancer (metastasis) [29]Unspecified dysbiosis (antibiotics, diet‐induced)Animal (mouse model; some human tissue data) Dysbiosis increased mast cells/collagen in mammary tissue, promoting metastasis. Blocking mast cell recruitment or function reduced metastasis.This study links gut microbiota imbalance to pro‐metastatic immune changes in breast cancer. Prostate cancer (CRPC) [10] Ruminococcus gnavus , Prevotella stercorea Animal (mouse tumor models) + human data Androgen deprivation therapy (ADT) promoted R. gnavus , which restored androgens and tumor growth whereas administering Prevotella stercorea or fecal transplants from hormone‐sensitive patients slowed tumor growth.These findings demonstrate a causal “gut–prostate axis”: commensal bacteria can drive hormone‐dependent cancer progression by metabolic activity, whereas other taxa (Prevotella) can be protective. Multiple myeloma (blood cancer) [11] Klebsiella pneumoniae , Prevotella heparinolytica Human (microbiome analysis) + Animal (mice) Altered gut microbiota enhanced MM via glutamine production and Th17 migration to the bone marrow.Conversely, butyrate‐producer ( Eubacterium hallii ) was associated with deeper remission (MRD‐negative status) in patients.These data reveal gut microbes can influence MM via metabolic and immune pathways. Chemotherapy‐assisted (lung and ovarian cancers) [9] Enterococcus hirae , Barnesiella intestinihominis Animal (tumor models + antibiotics) + Human correlates Cyclophosphamide efficacy was shown to depend on these microbes to enhance CD8+ T‐cell/Treg ratio and IFN‐γ–producing γδ T cells tumor responses.Importantly, cancer patients mounting specific Th1 immune responses against E. hirae or B. intestinihominis exhibited longer progression‐free survival when treated with chemo‐immunotherapy.This suggests these gut species (“oncomicrobiotics”) can enhance chemotherapy's tumor control. Note: This table summarizes key studies investigating the role of gut microbial taxa in modulating tumor behavior across various cancer types, using either animal models or human observational/interventional data. Highlighted mechanisms include microbiota‐driven effects on immune modulation, tumor metabolism, and response to checkpoint inhibitors or chemotherapy.Abbreviations: γδ T cells, gamma delta T lymphocytes; ADT, androgen deprivation therapy; CRPC, castration‐resistant prostate cancer; FMT, fecal microbiota transplantation; IL, interleukin; MRD, minimal residual disease; NSCLC, non–small cell lung cancer; PD‐1, programmed cell death protein‐1; PD‐L1, programmed death‐ligand 1; SCFA, short‐chain fatty acids. Gut microbiota–cancer interactions across human and animal studies. Germ‐free or antibiotic‐treated mice (Kras^G12D^/+; p53^−/−^ lung tumor model) developed fewer tumors. Germ‐free or antibiotic‐treated mice (Kras^G12D^/+; p53^−/−^ lung tumor model) developed fewer tumors. Gut microbes promoted tumor via IL‐1β/IL‐23 signaling and γδ T cell expansion. Gut microbes promoted tumor via IL‐1β/IL‐23 signaling and γδ T cell expansion. Removing gut microbes or blocking γδ T cells suppressed microbiota‐driven immune activation to lung cancer growth. Removing gut microbes or blocking γδ T cells suppressed microbiota‐driven immune activation to lung cancer growth. Lower gut diversity in patients; high A. muciniphila correlated with longer progression‐free survival. Lower gut diversity in patients; high A. muciniphila correlated with longer progression‐free survival. Other taxa (e.g., Alistipes onderdonkii , Ruminococcus) serve as prognostic biomarkers or therapeutic targets in NSCLC. Other taxa (e.g., Alistipes onderdonkii , Ruminococcus) serve as prognostic biomarkers or therapeutic targets in NSCLC. Bifidobacterium enhanced dendritic cell and CD8+ T‐cell function, to a similar extent as anti–PD‐L1 immunotherapy; combination nearly abolished tumor growth. Bifidobacterium enhanced dendritic cell and CD8+ T‐cell function, to a similar extent as anti–PD‐L1 immunotherapy; combination nearly abolished tumor growth. This study was among the first to show that a gut commensal can boost systemic anti‐cancer immunity. This study was among the first to show that a gut commensal can boost systemic anti‐cancer immunity. Responders had higher microbiome α‐diversity and higher abundance of Ruminococcaceae; responder‐FMT (Fecal microbiota transplant) improved tumor control in mice non‐responders. Responders had higher microbiome α‐diversity and higher abundance of Ruminococcaceae; responder‐FMT (Fecal microbiota transplant) improved tumor control in mice non‐responders. This indicates the gut microbiota composition causally influenced immunotherapy efficacy in melanoma. This indicates the gut microbiota composition causally influenced immunotherapy efficacy in melanoma. Antibiotic use linked to poorer outcomes in advanced lung, renal, and bladder cancer patients. Antibiotic use linked to poorer outcomes in advanced lung, renal, and bladder cancer patients. Certain gut bacteria, notably Akkermansia muciniphila (and some Ruminococcus spp.) restored PD‐1 efficacy in mice. Certain gut bacteria, notably Akkermansia muciniphila (and some Ruminococcus spp.) restored PD‐1 efficacy in mice. This demonstrates specific gut microbes (like Akkermansia) can enhance anti‐tumor immunity and improve immunotherapy success. This demonstrates specific gut microbes (like Akkermansia) can enhance anti‐tumor immunity and improve immunotherapy success. Dysbiosis increased mast cells/collagen in mammary tissue, promoting metastasis. Blocking mast cell recruitment or function reduced metastasis. Dysbiosis increased mast cells/collagen in mammary tissue, promoting metastasis. Blocking mast cell recruitment or function reduced metastasis. This study links gut microbiota imbalance to pro‐metastatic immune changes in breast cancer. This study links gut microbiota imbalance to pro‐metastatic immune changes in breast cancer. Androgen deprivation therapy (ADT) promoted R. gnavus , which restored androgens and tumor growth whereas administering Prevotella stercorea or fecal transplants from hormone‐sensitive patients slowed tumor growth. Androgen deprivation therapy (ADT) promoted R. gnavus , which restored androgens and tumor growth whereas administering Prevotella stercorea or fecal transplants from hormone‐sensitive patients slowed tumor growth. These findings demonstrate a causal “gut–prostate axis”: commensal bacteria can drive hormone‐dependent cancer progression by metabolic activity, whereas other taxa (Prevotella) can be protective. These findings demonstrate a causal “gut–prostate axis”: commensal bacteria can drive hormone‐dependent cancer progression by metabolic activity, whereas other taxa (Prevotella) can be protective. Altered gut microbiota enhanced MM via glutamine production and Th17 migration to the bone marrow. Altered gut microbiota enhanced MM via glutamine production and Th17 migration to the bone marrow. Conversely, butyrate‐producer ( Eubacterium hallii ) was associated with deeper remission (MRD‐negative status) in patients. Conversely, butyrate‐producer ( Eubacterium hallii ) was associated with deeper remission (MRD‐negative status) in patients. These data reveal gut microbes can influence MM via metabolic and immune pathways. These data reveal gut microbes can influence MM via metabolic and immune pathways. Cyclophosphamide efficacy was shown to depend on these microbes to enhance CD8+ T‐cell/Treg ratio and IFN‐γ–producing γδ T cells tumor responses. Cyclophosphamide efficacy was shown to depend on these microbes to enhance CD8+ T‐cell/Treg ratio and IFN‐γ–producing γδ T cells tumor responses. Importantly, cancer patients mounting specific Th1 immune responses against E. hirae or B. intestinihominis exhibited longer progression‐free survival when treated with chemo‐immunotherapy. Importantly, cancer patients mounting specific Th1 immune responses against E. hirae or B. intestinihominis exhibited longer progression‐free survival when treated with chemo‐immunotherapy. This suggests these gut species (“oncomicrobiotics”) can enhance chemotherapy's tumor control. This suggests these gut species (“oncomicrobiotics”) can enhance chemotherapy's tumor control. Note: This table summarizes key studies investigating the role of gut microbial taxa in modulating tumor behavior across various cancer types, using either animal models or human observational/interventional data. Highlighted mechanisms include microbiota‐driven effects on immune modulation, tumor metabolism, and response to checkpoint inhibitors or chemotherapy. Abbreviations: γδ T cells, gamma delta T lymphocytes; ADT, androgen deprivation therapy; CRPC, castration‐resistant prostate cancer; FMT, fecal microbiota transplantation; IL, interleukin; MRD, minimal residual disease; NSCLC, non–small cell lung cancer; PD‐1, programmed cell death protein‐1; PD‐L1, programmed death‐ligand 1; SCFA, short‐chain fatty acids. Furthermore, the gut microbiota regulates cytokine synthesis, which in turn modulates inflammatory signaling and disrupts intestinal homeostasis [30, 31]. Additionally, by affecting the host's immunological responses, the gut microbiota modifies the effectiveness of immune checkpoint inhibitors, including anti‐Programmed Cell Death‐1 (PD‐1) and anti‐CTLA‐4 therapies [32]. In a seminal study, Zitvogel et al. observed that the effectiveness of anti‐CTLA‐4 therapy was reduced in the absence of gut commensal bacteria and efficacy increased considerably when two species from the Bacteroidales order (phylum Bacteroidetes) and one species from the Burkholderiales order (Proteobacteria phylum) colonized the mice [33]. Similarly, Gajewski et al. (2015) reported that mice demonstrating stronger anti‐tumor responses to anti‐PD‐1Ab had significantly higher levels of Bifidobacterium species (phylum Actinobacteria) [6]. Among the numerous metabolites produced by the gut microbiota, SCFAs, mainly butyrate, propionate, and acetate are particularly critical. These SCFAs, derived from the fermentation of dietary fibers, support intestinal epithelial barrier integrity. Butyrate, for instance, stabilizes the hypoxia‐inducible factor (HIF), a transcription factor essential for epithelial barrier function, and regulates tight junction formation, as demonstrated in both in vitro systems and murine models. Furthermore, butyrate modulates immune responses by promoting Treg differentiation, thereby reducing intestinal inflammation [34]. Through the inhibition of histone deacetylase (HDAC), butyrate and propionate can alter inflammatory responses in the gut mucosa. Butyrate has been demonstrated in earlier studies to reduce colonic inflammation through HDAC1‐dependent Fas overexpression. Butyrate can stimulate Treg differentiation and boost Th1 and Th17 cell production. Additionally, it has been demonstrated that SCFA generated from microbiota accelerates the cellular metabolism of antigen‐activated CD8+ T cells and improves their differentiation into long‐term memory T cells [35]. While SCFAs have garnered significant attention, multi‐omics studies reveal that gut microbiota produce a broad‐spectrum of bioactive metabolites with epigenetic regulatory potential [36]. These metabolites influence carcinogenesis through DNA methylation, histone modifications, and non‐coding RNA‐mediated gene regulation. Altered gut microbial composition may promote tumorigenesis by inducing aberrant DNA methylation and silencing tumor suppressor genes [37]. Furthermore, the gut microbiota can affect gene regulatory networks implicated in carcinogenesis by modifying the expression of non‐coding RNA [38]. A deeper understanding of these interactions can help identify and develop novel therapeutic intervention pathways and shed light on the intricate relationship between the gut microbiota and cancer. The gut microbiota also exerts oncogenic or tumor‐suppressive effects by modulating key signaling pathways, such as PI3K/AKT, NF‐κB, and Wnt/β‐catenin. The PI3K/AKT/mTOR axis is a critical regulator of cancer cell growth, metabolism, and survival [39]. Microbial imbalances can also activate NF‐κB signaling, resulting in chronic inflammation and a pro‐tumorigenic microenvironment [40]. Emerging evidence has introduced the concept of microbiome‐mediated secretory phenotype (MMSP) as a critical link between gut microbial dysbiosis and extraintestinal tumorigenesis. It describes a change in host secretory activity that is driven by gut microbiota‐derived metabolites. This will result in increased production of cytokines, growth factors, and chemokines that affect the tissue distant from the gut. This way, the gut microbiota can positively or negatively influence the process of tumorigenesis [41]. MMSP brings together several mechanisms, including microbial metabolite signaling, immune cell activation, and chronic low‐grade inflammation. By altering immune surveillance and local tissue environment, MMSP alters cancer initiation, progression, and prognosis. This mechanism explains how disturbances in gut microbiota produce systemic effects relevant to extraintestinal malignancies [42]. Emerging evidence supports a central role for microbiome‐driven metabolic dysfunction as a systemic mediator of extra‐intestinal carcinogenesis. Metabolic dysfunction‐associated fatty liver disease (MAFLD/NAFLD) reflects a state of systemic inflammatory and metabolic dysregulation linked to malignancies beyond the liver. In pancreatic cancer, mechanisms including dysbiosis, insulin resistance, adipocytokine imbalance, and pro‐inflammatory signaling have been implicated in tumor development [43]. Similarly, metabolic dysfunction has been identified as an independent risk factor for Helicobacter pylori –negative gastric cancer, while the coexistence of metabolic dysfunction and alcohol exposure (MetALD) exerts synergistic effects on esophageal cancer recurrence [44, 45]. Collectively, these data support a unifying paradigm in which microbiome‐mediated metabolic alterations promote oncogenesis across multiple extra‐intestinal sites. Gut Microbiota in Solid Tumor Cancers Breast Cancer Breast cancer (BC) provides a perfect example of how gut microbiota can influence a non‐gastrointestinal tumor through both metabolic and immune pathways. One major link is via estrogen metabolism. The collection of gut microbial genes known as the “estrobolome” encodes enzymes (like β‐glucuronidases) that modulate estrogen circulation and excretion. In a healthy state, excess estrogens are conjugated in the liver and excreted in bile; however, gut bacteria with β‐glucuronidase can deconjugate estrogen, reactivating it for reabsorption into the bloodstream. Dysbiosis that increases β‐glucuronidase activity leads to higher free estrogen levels, a known risk factor for estrogen receptor–positive BC [46]. Studies have found that postmenopausal women with BC often harbor more abundant estrogen‐deconjugating bacteria (e.g., certain Clostridia or Veillonella species) in their gut, potentially elevating circulating estrogen and driving hormone‐dependent tumor growth [47]. Perturbations in this microbiota–estrobolome axis can thus contribute to BC risk and progression by prolonging the estrogenic stimulation of mammary cells [48, 49]. In fact, a diverse array of gut bacteria (including Alistipes, Bacteroides, Bifidobacterium, Collinsella, Lactobacillus, and others) are capable of producing β‐glucuronidase [50]. The relative abundance of these taxa in an individual's gut may influence not only cancer risk but also responses to hormone‐based therapies. There is speculation that gut microbes might affect the metabolism or enterohepatic cycling of drugs like tamoxifen or aromatase inhibitors, although direct clinical evidence is still emerging [51]. Nonetheless, high‐fiber diets (prebiotic intake) can reduce circulating estrogens by promoting microbial metabolism that favors estrogen excretion, aligning with epidemiological observations that fiber intake is associated with reduced BC risk [52, 53]. Beyond systemic hormones, the gut microbiota can impact breast tumors through immune modulation and even direct translocation of bacteria or their toxins to the mammary gland [54]. It was long assumed that breast tissue was sterile, but we now know a resident breast microbiome exists [55, 56]. Commensal microbes or their products can reach breast tissue via circulation or immune cell trafficking. For example, the gut bacterium Enterotoxigenic Bacteroides fragilis (ETBF) produces a toxin (BFT) that, when chronically present, causes intestinal inflammation. Remarkably, ETBF has also been found colonizing mammary tissue in mice, where BFT induced hyperplasia of mammary epithelium and significantly accelerated tumor growth and metastasis in a breast cancer model via activation of β‐catenin and Notch signaling [57, 58]. Similarly, Fusobacterium nucleatum (more commonly linked to colon cancer) has been detected in human breast tumors and shown to promote breast cancer metastasis by binding to tumor cell surface glycans and activating TLR4/NF‐κB inflammatory pathways in the cancer cells [49, 59, 60]. These findings suggest that gut microbes (or oral microbes that pass through the gut) can disseminate to breast tissue and create a pro‐tumor microenvironment through inflammation and direct oncogenic signaling. Immunologically, the gut microbiota influences systemic and local immune responses pertinent to BC. Patients with breast cancer often exhibit gut dysbiosis characterized by reduced overall microbial diversity [61, 62, 63]. Lower microbiome diversity has been correlated with higher levels of systemic inflammation (e.g., elevated IL‐6) and worse prognosis in BC [64, 65]. Gut microbes modulate the levels and function of immune cells infiltrating breast tumors. For instance, commensals like Akkermansia muciniphila can produce small cyclic dinucleotides (e.g., cdAMP) that activate the STING pathway, thereby inducing Type I interferons and repolarizing tumor‐associated macrophages toward an anti‐tumor phenotype [66]. Activation of STING by microbial signals enhances crosstalk between dendritic cells and NK cells, bolstering anti‐tumor immunity in breast cancer models [66]. On the other hand, gut dysbiosis that leads to a deficit of such beneficial signals may allow an immunosuppressive milieu to dominate. In a mouse model of BC, gut infection by H. hepaticus not only promoted tumor growth via neutrophils as mentioned, but also skewed macrophages toward an M2‐like, pro‐tumoral state, consistent with clinical observations that M2 macrophage infiltration correlates with poorer survival in breast cancer [66, 67, 68, 69]. These examples illustrate the complex immunomodulatory influence of gut microbes: they can drive either pro‐ or anti‐tumor immune pathways in breast cancer, depending on the microbial composition and the host context. Lung Cancer Although the lungs have their own microbiota, the gut microbiota can also influence lung cancer through systemic immune modulation. Microbe‐derived products from the gut can migrate via circulation to the lung and affect pulmonary immune homeostasis [70]. One way this manifests is in lung cancer patients' response to immunotherapy. Studies have shown that gut microbiota composition can predict which non‐small cell lung cancer (NSCLC) patients respond to PD‐1/PD‐L1 inhibitors [7, 27]. Patients with higher baseline gut microbial diversity and the presence of certain commensals (like Akkermansia muciniphila, Alistipes putredinis, and Bifidobacterium longum ) had improved objective response rates and longer progression‐free survival on anti‐PD‐1 therapy [7, 25, 71, 72]. In contrast, those with a dominance of potentially pathogenic genera or low diversity tended to have poorer outcomes [73]. It is thought that a healthy microbiota “primes” the systemic immune system, for example by increasing the pool of effector CD8+ T cells or modulating myeloid cells in a way that enhances anti‐tumor immunity in the lung microenvironment [33, 74, 75]. In support of this, fecal transplant experiments from ICI‐responsive patients have improved lung tumor control in mouse models [76]. Conversely, antibiotic‐induced dysbiosis can have a detrimental effect on lung cancer therapy. In large patient cohorts, use of antibiotics around the start of ICI treatment was associated with significantly shorter survival in advanced NSCLC [7, 77]. A meta‐analysis of over 2000 NSCLC patients found that antibiotics reduced median progression‐free survival by ~1.2 months and overall survival by ~6–7 months [78, 79]. This suggests that the gut microbiota is integral to mounting an effective anti‐cancer immune response in the lungs, such that disrupting it impairs therapy efficacy. Preclinical studies offer mechanistic insight: one study found that certain gut bacteria induce the maturation of lung‐resident dendritic cells and promote Th1 cytokine production in the lung, thereby enhancing T cell‐mediated clearance of tumors [33, 80]. Without these microbial signals, lung tumors more easily escape immune surveillance. Even outside the context of immunotherapy, systemic inflammation driven by gut dysbiosis can contribute to lung carcinogenesis [81]. For example, circulating LPS from a leaky gut can activate lung macrophages and epithelial cells to produce pro‐tumor cytokines. In models of chemical carcinogenesis in the lung, GF or antibiotic‐treated mice (lacking normal gut flora) often show reduced tumor burden, consistent with a role for microbes in promoting tumorigenic inflammation [82, 83, 84, 85]. However, more research is needed to delineate specific gut–lung signaling metabolites in lung cancer. Emerging data suggest that metabolites like SCFAs might play a protective role by maintaining anti‐inflammatory regulatory cells in the lung, whereas others like certain bile acids or N‐nitroso compounds could potentially promote lung tumorigenesis. Overall, the gut microbiome appears to influence lung cancer initiation and progression largely via immune modulation. Melanoma Melanoma has been at the forefront of microbiome–cancer research, largely because it was among the first diseases where gut microbial composition was linked to immunotherapy outcomes. Immune checkpoint blockade revolutionized melanoma treatment, but only a subset of patients derive durable benefit. Pioneering studies in 2015 and 2017 revealed that commensal gut bacteria can tip the scales of anti‐tumor immunity in melanoma [86]. Sivan et al. [6] famously demonstrated that mice with different gut microbiota had markedly different melanoma growth rates; cohousing or transferring stool between mice could transfer anti‐tumor immune phenotypes. They identified Bifidobacterium as a key genus in melanoma‐bearing mice improved tumor control as much as anti‐PD‐L1 therapy, and combined probiotic + anti‐PD‐L1 nearly eradicated tumors via enhanced dendritic cell and CD8+ T‐cell activity [73, 74, 87, 88]. Around the same time, Vétizou et al. found that Bacteroides species were required for optimal response to CTLA‐4 blockade in mice, as discussed earlier [33]. These discoveries in mice set the stage for human studies. In melanoma patients, gut microbiota profiles differ between responders and non‐responders to ICIs. Higher abundance of Faecalibacterium, Ruminococcaceae, and certain Bacteroidales has been associated with responders, whereas non‐responders often have more Bacteroidetes and Proteobacteria but lower overall diversity [71, 89, 90]. Responders' microbiomes tend to be enriched in fiber‐fermenting and butyrate‐producing bacteria, suggesting a link to SCFA‐mediated immune fitness [8, 91, 92, 93]. Fecal transplant trials in melanoma have provided proof‐of‐concept that manipulating the microbiome can alter clinical outcomes. Two landmark Phase I trials published in 2021 took stool from melanoma patients who responded to anti‐PD‐1 and administered it to a small group of refractory melanoma patients, alongside resuming anti‐PD‐1 therapy. In both studies, about one‐third of the previously resistant patients converted to responders after FMT, achieving tumor regression or disease control [85, 86]. These remarkable cases showed, for the first time in humans, that the gut microbiome can causally affect cancer treatment efficacy. More recently, a Phase I trial in 2023 confirmed that FMT plus anti‐PD‐1 is feasible and can induce responses in advanced melanoma, with ongoing work to identify which bacteria are mediating these benefits [28, 94]. Species repeatedly implicated include Akkermansia muciniphila , various Clostridiales (like Faecalibacterium prausnitzii ), and Bifidobacterium though inconsistent results across studies indicate that a consortium of bacteria or overall community balance, rather than a single microbe, likely underlies response [95, 96]. Apart from immunotherapy, the gut–skin immune axis also matters in melanoma biology. Commensal microbiota help calibrate systemic T cell responsiveness, which can affect how the immune system surveils melanoma cells. For instance, gut microbes can influence the activation state of skin‐homing CD4+ T cells and macrophages. Additionally, some microbial metabolites might suppress melanoma growth directly. Early evidence suggests that butyrate's HDAC inhibition can induce differentiation or apoptosis in melanoma cells, and other metabolites might affect melanoma cell metabolism. While such direct effects are less studied than immune effects, it remains an area of interest. Clinically, there is interest in whether baseline microbiome features can predict melanoma patient prognosis even without immunotherapy. Some studies have found that certain microbial signatures correlate with melanoma progression or metastasis risk, implying the microbiome's influence is not limited to treated patients. Thus, melanoma has led the way in demonstrating microbiome biomarkers and interventions for improving cancer outcomes [76, 97]. Prostate Cancer Compared to others, the gut microbiota's role in prostate cancer is less extensively characterized but is an emerging field of interest, particularly in the context of metabolic crosstalk and hormonal regulation (androgen signaling with testosterone and dihydrotestosterone acting on the androgen receptor, AR). Prostate cancer progression is primarily driven by AR signaling. Emerging evidence suggests that gut‐derived metabolites can antagonize AR signaling. In preclinical models, microbiota‐derived bile acids suppressed AR activity on immune cells, enhancing CD8+ T‐cell–mediated anti‐tumor responses. It is plausible that similar mechanisms could influence AR activity within tumor cells, potentially attenuating tumor growth or enhancing sensitivity to hormonal therapy [98]. Conversely, gut microbes have also been implicated in therapy resistance. A 2021 study demonstrated that certain bacteria can synthesize androgens, acting as an alternative testosterone source during androgen deprivation therapy. Eradicating these microbes via antibiotics reduced systemic androgen levels and delayed tumor progression in castration‐resistant prostate cancer models [99]. Further, diet‐driven microbial metabolites such as trimethylamine N‐oxide (TMAO) have been associated with aggressive phenotypes, possibly through pro‐inflammatory effects and tumor‐promoting immune profiles [100]. Although prostate tumors are often immunologically “cold”, gut microbiota may offer immunomodulatory potential. Preliminary evidence suggests that probiotics can enhance tumor‐infiltrating lymphocytes in prostate cancer models. Given the anatomical distance between the prostate and the gut, such effects are likely mediated via systemic pathways, including circulating metabolites and immune cell conditioning [101]. Microbiome‐Targeted Interventions in Cancer Therapy Growing evidence suggests that the gut microbiota can profoundly influence cancer development and treatment outcomes (Figure 3) [102]. Several approaches are under investigation to either boost anti‐tumor immunity or mitigate treatment side effects by shifting the gut's microbial composition or function. Gut microbiota interventions for cancer therapy. Modulating the gut microbiota through approaches such as antibiotics, fecal microbiota transplantation (FMT), probiotics, dietary interventions, prebiotics, and emerging microbial‐based therapies can significantly influence immunotherapy outcomes. Narrow‐spectrum antibiotics like vancomycin and tigecycline may be beneficial, whereas broad‐spectrum agents often reduce treatment efficacy. Probiotics, including Lactobacillus, Bifidobacterium, Clostridium butyricum , and Akkermansia, help maintain a favorable microbial balance. Dietary and prebiotic interventions—such as inulin gel, pectin, high‐fiber diets, fasting‐mimicking regimens, and ketogenic diets—further support gut modulation and immune function. In addition, emerging approaches using engineered microbes, microbial peptides, and microbial metabolites are being explored. Together, these strategies shape the gut microbiome to strengthen immune responses and improve immunotherapy effectiveness. Fecal Microbiota Transplantation (FMT) Concept and Early Trials FMT involves transferring stool (and its community of microbes) from a healthy donor to a cancer patient to reset the gut microbiome. In oncology, FMT has shown potential in enhancing immunotherapy responses. Small trials in advanced melanoma demonstrated that FMT from anti–PD‐1 responders (B. adolescentis enriched) enabled some refractory patients to respond when rechallenged with PD‐1 inhibitors [103]. Further studies confirmed achieving similar benefits with FMT [28, 104]. More recently, a Phase I trial (MELRESIST trial) further supported that FMT plus pembrolizumab is safe and can induce tumor regression in a subset of anti‐PD‐1–resistant patients [105]. Beyond melanoma, FMT studies in lung, liver, and other malignancies showed disease control in ~46% of patients receiving FMT plus anti–PD‐1 therapy, though objective response rates were modest [94, 106, 107]. These trials indicate that modifying the gut microbiome via FMT can reprogram the host immune system to better fight cancer. Responders to post‐FMT immunotherapy have shown increases in beneficial gut bacteria (such as Akkermansia and Bifidobacterium) along with heightened CD8+ T‐cell activation and greater immune cell infiltration into their tumors. This links specific microbiome changes to improved anti‐tumor immunity [91] (Table 3). TABLE 3Key microbiome–cancer associations from preclinical and clinical studies: insights into mechanisms and therapeutic implications.Study (author, year)Cancer typeStudy designKey findingsGopalakrishnan et al. 2018 [27]Various (Melanoma, NSCLC, RCC)Multicenter cohort study with FMT and immunotherapyFMT enhanced ICI response in some solid tumors; higher SCFA levels in respondersBaruch et al. 2021 [103]MelanomaOpen‐label trial; FMT + anti–PD‐1 in non‐responders3/10 (1‐CR; 2‐PR) patients had clinical benefit; microbiota shift with increased beneficial taxaDavar et al. 2021 [104]MelanomaOpen‐label trial; FMT + anti–PD‐1 in non‐responders6/15 (1‐CR; 2‐PR; 3‐SD) had clinical benefit; higher Akkermansia/Bifidobacterium post‐FMTRouty et al. 2023 [28]MelanomaOpen‐label trial; FMT + anti–PD‐1 in non‐responders13/20 (4‐CR; 9‐PR) had clinical benefitRobinson et al. 2023 [108]MelanomaPhase I trial of FMT + pembrolizumabFMT + anti–PD‐1 was safe; induced partial responses in some patientsKim et al. 2024 [94]GC, ESCC, HCCOpen‐label trial; FMT + anti–PD‐1 in non‐responders6/13 (1‐PR; 5‐SD) patients had clinical benefit; microbiota shift with increased beneficial taxa Note: This table summarizes key studies investigating the role of specific gut microbial taxa in various cancer types, highlighting the study design (animal models or human cohorts), microbiota investigated, and principal findings. Cancer types include non‐small cell lung cancer (NSCLC), melanoma, prostate cancer (castration‐resistant prostate cancer, CRPC), breast cancer, multiple myeloma (MM), and chemotherapy‐assisted cancers. Notable mechanisms involve immune modulation (e.g., CD8+ T cells, Th17 cells), microbial metabolism (e.g., glutamine, short‐chain fatty acids [SCFAs]), and interactions with immunotherapy or androgen deprivation therapy (ADT).Abbreviations: ADT, androgen deprivation therapy; CRPC, castration‐resistant prostate cancer; FMT, fecal microbiota transplantation; MM, multiple myeloma; MRD, minimal residual disease; NSCLC, non‐small cell lung cancer; PD‐1/PD‐L1, programmed cell death protein 1 and its ligand. Key microbiome–cancer associations from preclinical and clinical studies: insights into mechanisms and therapeutic implications. Note: This table summarizes key studies investigating the role of specific gut microbial taxa in various cancer types, highlighting the study design (animal models or human cohorts), microbiota investigated, and principal findings. Cancer types include non‐small cell lung cancer (NSCLC), melanoma, prostate cancer (castration‐resistant prostate cancer, CRPC), breast cancer, multiple myeloma (MM), and chemotherapy‐assisted cancers. Notable mechanisms involve immune modulation (e.g., CD8+ T cells, Th17 cells), microbial metabolism (e.g., glutamine, short‐chain fatty acids [SCFAs]), and interactions with immunotherapy or androgen deprivation therapy (ADT). Abbreviations: ADT, androgen deprivation therapy; CRPC, castration‐resistant prostate cancer; FMT, fecal microbiota transplantation; MM, multiple myeloma; MRD, minimal residual disease; NSCLC, non‐small cell lung cancer; PD‐1/PD‐L1, programmed cell death protein 1 and its ligand. Challenges and Alternatives While FMT has demonstrated therapeutic potential, its clinical application in oncology remains experimental and constrained by important limitations. A major concern is the risk of pathogen transmission, including multidrug‐resistant organisms, despite existing donor screening protocols, reflecting the incomplete characterization of the gut microbiome and limitations of current regulatory frameworks [99, 100]. In addition, there is no consensus regarding optimal donor selection, preparation methods, or delivery routes, contributing to substantial heterogeneity in treatment response. Beyond safety, biological and translational uncertainties persist. The specific microbial taxa or functional pathways responsible for therapeutic benefit remain incompletely defined, and inter‐individual variability in baseline microbiome composition may significantly influence engraftment and response. Furthermore, logistical challenges such as donor identification, processing, storage, and patient acceptability limit scalability, while a proportion of patients fail to respond despite successful microbiome transfer, underscoring incomplete mechanistic understanding [109, 110, 111]. To overcome these limitations, defined live biotherapeutic products (LBPs) are being developed as more standardized alternatives to whole FMT. These approaches aim to deliver selected microbial consortia with presumed functional benefit while improving reproducibility and regulatory control [112]. Strategies include isolating key taxa associated with immunotherapy response such as Faecalibacterium, Akkermansia, and Enterococcus. Early‐phase clinical trials evaluating agents such as MRx0518, multistrain Bifidobacterium consortia, and SER‐401 are ongoing in patients receiving immunotherapy [113]. However, these approaches remain in early clinical development, with unresolved questions regarding optimal strain selection, dosing, durability of response, and long‐term safety. Collectively, these considerations highlight that, although microbiome‐based therapies hold considerable promise, their integration into routine oncology practice will require rigorous standardization, mechanistic validation, and large‐scale clinical trials. Probiotics Potential Benefits Probiotics may support cancer care by restoring microbiome balance. Preclinical models have shown promising results: for instance, Lactobacillus acidophilus slowed tumor growth and prolonged survival in mice with BC, potentially by boosting NK and CD8+ T‐cell activity and promoting Th1‐type immune responses (↑IL‐12, IFN‐γ). Some strains also produce bacteriocins with direct anti‐tumor effects. A Japanese cohort study found lower BC incidence in women who consumed Lactobacillus casei Shirota–fermented milk since adolescence. In colorectal cancer, probiotics may reduce postoperative infections, inflammation, and recurrence risk, likely via improved gut barrier function and immune surveillance. Additionally, specific Lactobacillus strains alleviate side effects of chemotherapy and radiation‐induced diarrhea [114, 115, 116]. Cautionary Findings Not all probiotic use is beneficial. In melanoma patients on immunotherapy, those using OTC probiotics had lower microbiome diversity and worse outcomes than non‐users. Conversely, a high‐fiber diet (> 20 g/day) correlated with longer progression‐free survival, especially when probiotics were avoided. These findings suggest that generic probiotics may disrupt the native microbiota, displacing more beneficial strains. The variability in probiotic effects likely stems from differences in strains, dosages, and individual microbiomes. Therefore, a one‐size‐fits‐all probiotic from the store may not replicate the nuanced ecosystem benefits of a naturally high‐diversity diet [117]. Next‐Generation Probiotics Going forward, probiotic design is moving toward more targeted strains that are known “keystone” species like Akkermansia muciniphila and Faecalibacterium prausnitzii , which are linked to immune and metabolic health. Though not yet commercially available, these next‐generation probiotics are in development. Synthetic biology is also enabling engineered strains to modulate immunity precisely at the tumor site [116, 118]. Prebiotics and Dietary Modulation Diet is a powerful modulator of the gut microbiome. Prebiotics promote beneficial bacteria, especially those producing SCFAs. Diets rich in fruits, vegetables, legumes, and whole grains increase microbial diversity, while high‐fat, low‐fiber diets promote pro‐inflammatory, bile‐tolerant species like Proteobacteria and reduce commensals [119, 120]. Epidemiological data suggest 30%–50% of cancers, including colorectal and breast cancer, are diet‐linked. In melanoma, higher dietary fiber intake was associated with improved responses to PD‐1 inhibitors. Mechanistically, SCFA‐producing microbes enhance CD8+ T‐cell activation and anti‐tumor immunity, a finding supported by preclinical tumor models. Conversely, low‐fiber or processed food diets can impair immune responses, and obesity is linked to systemic inflammation, altered microbiota, and reduced treatment efficacy [121, 122]. Specific nutrients also influence tumor biology via the microbiome: Omega‐3 fatty acids enrich anti‐inflammatory microbes and reduce pro‐tumor signals [85]. Omega‐3 fatty acids enrich anti‐inflammatory microbes and reduce pro‐tumor signals [85]. High‐fat diets raise levels of 27‐hydroxycholesterol (27HC), a pro‐estrogenic metabolite linked to breast tumor growth [83]. High‐fat diets raise levels of 27‐hydroxycholesterol (27HC), a pro‐estrogenic metabolite linked to breast tumor growth [83]. Alcohol alters gut microbiota and estrogen metabolism (via the “estrobolome”), increasing breast cancer risk in postmenopausal women [123]. Alcohol alters gut microbiota and estrogen metabolism (via the “estrobolome”), increasing breast cancer risk in postmenopausal women [123]. Given the evidence, some oncologists now encourage dietary modulation as an adjunct to treatment. Patients on immunotherapy, for example, may be advised to eat a plant‐rich, high‐fiber diet and include fermented foods (like yogurt or kefir) to support a diverse microbiome, while being cautious about taking unnecessary probiotic supplements or antibiotics during treatment. Any dietary intervention for cancer patients must be approached with scientific rigor and individualized care as they have unique nutritional needs, and extreme diets can carry risks if not properly managed. Nonetheless, diet‐based strategies are attractive because they are low‐cost and low‐toxicity methods to favorably shape the microbiome. Several clinical trials are ongoing to formally test diet interventions in cancer: for instance, a trial in melanoma and lung cancer patients is comparing a high‐fiber diet versus a control diet at the start of anti–PD‐1 therapy (to see if fiber intake impacts response rates and gut microbiota profiles), and another trial is examining how a ketogenic (high‐fat, low‐carb) diet might alter the microbiome and affect cancer outcomes. The results of these studies will help determine how best to prescribe “food as medicine” in oncology. Other Microbiome‐Based Strategies Beyond FMT, probiotics, and diet, researchers are exploring additional microbiome‐targeted interventions: Postbiotics: These are beneficial microbial metabolites or components administered directly, without live bacteria. Examples include SCFAs (like butyrate or propionate) produced by fiber‐fermenting gut bacteria, as well as bacterial polysaccharides or enzymes. The idea is to deliver the beneficial molecules that a healthy microbiome would naturally produce. For instance, oral butyrate supplements or high‐resistant‐starch diets (which gut microbes convert into butyrate) are being tested to see if they can reduce colorectal polyp formation and modulate immune checkpoints in colorectal cancer. In patients receiving immunotherapy, there is interest in providing SCFAs (via specialized oral formulations or even rectal enemas) to potentially boost response rates since some studies have noted higher fecal SCFA levels in responders to checkpoint blockade. While postbiotic therapy is still experimental, it could bypass the need to engraft live bacteria by instead delivering key microbial products to the patient [124, 125]. Postbiotics: These are beneficial microbial metabolites or components administered directly, without live bacteria. Examples include SCFAs (like butyrate or propionate) produced by fiber‐fermenting gut bacteria, as well as bacterial polysaccharides or enzymes. The idea is to deliver the beneficial molecules that a healthy microbiome would naturally produce. For instance, oral butyrate supplements or high‐resistant‐starch diets (which gut microbes convert into butyrate) are being tested to see if they can reduce colorectal polyp formation and modulate immune checkpoints in colorectal cancer. In patients receiving immunotherapy, there is interest in providing SCFAs (via specialized oral formulations or even rectal enemas) to potentially boost response rates since some studies have noted higher fecal SCFA levels in responders to checkpoint blockade. While postbiotic therapy is still experimental, it could bypass the need to engraft live bacteria by instead delivering key microbial products to the patient [124, 125]. Antibiotic Stewardship: Oncologists are increasingly aware that broad‐spectrum antibiotics can disrupt the gut microbiota and may negatively impact cancer outcomes. Retrospective studies have found that cancer patients who received antibiotics around the time of immunotherapy had poorer responses because antibiotics wiped out beneficial microbes critical for priming anti‐tumor immunity. Oncology teams are developing guidelines to avoid or minimize antibiotic use during immune‐based therapies, unless absolutely necessary. When antibiotics are essential (for treating serious infections), efforts are made to use the most narrow‐spectrum agents and the shortest duration possible to limit collateral damage to the microbiome. In parallel, for patients who do require long‐term antibiotics or who have severe dysbiosis, strategies for microbiome “rehabilitation” are considered—such as using tailored probiotics or diet adjustments post‐antibiotic—to restore some of the lost beneficial flora [33, 126]. Antibiotic Stewardship: Oncologists are increasingly aware that broad‐spectrum antibiotics can disrupt the gut microbiota and may negatively impact cancer outcomes. Retrospective studies have found that cancer patients who received antibiotics around the time of immunotherapy had poorer responses because antibiotics wiped out beneficial microbes critical for priming anti‐tumor immunity. Oncology teams are developing guidelines to avoid or minimize antibiotic use during immune‐based therapies, unless absolutely necessary. When antibiotics are essential (for treating serious infections), efforts are made to use the most narrow‐spectrum agents and the shortest duration possible to limit collateral damage to the microbiome. In parallel, for patients who do require long‐term antibiotics or who have severe dysbiosis, strategies for microbiome “rehabilitation” are considered—such as using tailored probiotics or diet adjustments post‐antibiotic—to restore some of the lost beneficial flora [33, 126]. Finally, the concept of precision microbiome therapy entails analyzing a patient's baseline microbiome and tailoring an intervention specific to their deficiencies or excesses. For example, if a patient lacks Akkermansia and Faecalibacterium, a physician might recommend certain prebiotics or an FMT from a donor high in those taxa. Machine learning models can now use microbiome data to predict a patient's likely response to treatment, potentially guiding who might benefit most from microbiome modulation. Though still early, these developments foreshadow a future in which microbiome analysis and manipulation become integrated into standard cancer care. Finally, the concept of precision microbiome therapy entails analyzing a patient's baseline microbiome and tailoring an intervention specific to their deficiencies or excesses. For example, if a patient lacks Akkermansia and Faecalibacterium, a physician might recommend certain prebiotics or an FMT from a donor high in those taxa. Machine learning models can now use microbiome data to predict a patient's likely response to treatment, potentially guiding who might benefit most from microbiome modulation. Though still early, these developments foreshadow a future in which microbiome analysis and manipulation become integrated into standard cancer care. Future Directions The gut microbiota has emerged as a central modulator of oncogenesis and therapeutic responsiveness in extraintestinal malignancies. They intricately regulate host immunity, metabolic signaling, and systemic inflammation and thereby shape the tumor microenvironment by modulating immune cell trafficking (e.g., augmenting cytotoxic CD8+ T‐cell infiltration or fostering immunosuppressive Treg/Th17 expansion) along with generating bioactive metabolites such as SCFA and bile acid derivatives that exert immunomodulatory or pro−/anti‐tumorigenic effects [95, 104]. While therapeutic strategies such as FMT, probiotics, and dietary regimens represent an important shift in oncology, much of the current mechanistic evidence remains correlative. A key limitation is the substantial inter‐individual heterogeneity in microbiome composition, shaped by variables including diet, geography, antibiotic exposure, cancer subtype, and host genetics. Consequently, findings in one tumor context (e.g., melanoma) may not extrapolate reliably to others (e.g., lung or breast cancer). This underscores the need for standardization in microbiome sampling, sequencing, and analysis pipelines, as well as robust, multicenter clinical trials [91, 92]. Emerging delivery approaches such as nanoparticle‐based systems, may help address these limitations by allowing more targeted and controlled modulation of the gut microbiome. Polymeric, lipid‐based, or microbiota‐responsive nanoparticles can deliver prebiotics, probiotics, SCFAs, or immunomodulatory compounds selectively to the gut, enhancing stability, efficacy, and safety [127]. A key advancement lies in shifting from descriptive taxonomy to functional microbiomics, leveraging multi‐omics platforms to identify microbially derived metabolites or pathways that can serve as targets for both stratification and intervention. Equally important is understanding the bidirectional impact of cancer therapies on the microbiome. Treatments like chemotherapy and radiotherapy can induce dysbiosis, potentially exacerbating toxicities and diminishing efficacy. Recent advances in technologies such as spatial transcriptomics, metabolomics, and bioinformatic tools are helping researchers to better understand how the microbiome interacts with host tissue across different organs [128]. Precision microbial therapeutics must also evolve. While FMT and probiotics have demonstrated benefit, non‐responsiveness remains a challenge, potentially due to poor engraftment or tumor‐specific resistance. Next‐generation probiotics built around species like Akkermansia muciniphila and Faecalibacterium prausnitzii offer potential for more personalized approaches, but require careful regulatory oversight. A particularly promising frontier is the study of intratumoral microbiota, referring to bacteria, fungi, and viruses residing within tumor tissue. These microbes can influence how tumors respond to therapy. Some, like Bifidobacterium and Akkermansia, boost anti‐tumor immunity by enhancing CD8+ T‐cell and NK‐cell activity. Others, including Fusobacterium nucleatum and Bacteroides fragilis , can suppress immune responses through Treg induction, myeloid cell modulation, or reactive oxygen species. Engineered bacterial vectors (e.g., Clostridium, Salmonella) are being developed to deliver therapeutics directly into the tumor milieu, offering a novel delivery mechanism. Understanding how microbes within tumors interact with the gut microbiota may help in explaining the differences in immune response and treatment outcomes in extraintestinal cancers [129]. In conclusion, the gut microbiota stands at the nexus of immunity and metabolism, exerting influence on cancers throughout the body. Future directions include: (i) Clinical validation of microbiome‐targeted therapies, (ii) development of defined microbial consortia or metabolite‐based agents, and (iii) integration of microbiome profiling into precision oncology frameworks. With interdisciplinary collaboration spanning oncology, microbiology, immunology, and bioinformatics, the next decade may transform the microbiome from a modifiable risk factor into a therapeutic ally. Funding The authors have nothing to report. Ethics Statement The authors have nothing to report. Consent The authors have nothing to report. Conflicts of Interest The authors declare no conflicts of interest. Acknowledgments Dr. Ajit Sood and Dr. Vineet Ahuja for being the guiding force for this project and many more. Data Availability Statement Data sharing not applicable to this article as no datasets were generated or analyzed during the current study. All data supporting the findings of this study is available within the paper. References Associated Data Data Availability Statement Data sharing not applicable to this article as no datasets were generated or analyzed during the current study. All data supporting the findings of this study is available within the paper.